HC Wainwright Forecasts Strong Price Appreciation for Structure Therapeutics (NASDAQ:GPCR) Stock

Structure Therapeutics (NASDAQ:GPCR) had its price objective hoisted by equities researchers at HC Wainwright from $90.00 to $114.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 80.87% from the stock’s previous close.

Several other brokerages have also weighed in on GPCR. Citizens Jmp cut their price objective on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a report on Friday, February 27th. Stifel Nicolaus increased their price target on Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, December 8th. The Goldman Sachs Group upgraded Structure Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 20th. BMO Capital Markets reiterated an “outperform” rating on shares of Structure Therapeutics in a report on Tuesday, January 6th. Finally, Wall Street Zen raised Structure Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Structure Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.90.

Structure Therapeutics Stock Up 0.2%

Shares of GPCR opened at $63.03 on Monday. The stock’s fifty day simple moving average is $75.24 and its 200-day simple moving average is $47.54. The firm has a market capitalization of $4.45 billion, a PE ratio of -79.78 and a beta of -1.80. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.14). Analysts anticipate that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Several large investors have recently modified their holdings of GPCR. Envestnet Asset Management Inc. bought a new position in shares of Structure Therapeutics during the 2nd quarter valued at about $221,000. Assetmark Inc. raised its holdings in Structure Therapeutics by 39.9% during the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock worth $60,000 after buying an additional 820 shares during the period. Bank of Montreal Can lifted its stake in Structure Therapeutics by 9.1% in the second quarter. Bank of Montreal Can now owns 58,073 shares of the company’s stock valued at $1,224,000 after buying an additional 4,838 shares in the last quarter. Quinn Opportunity Partners LLC boosted its holdings in shares of Structure Therapeutics by 90.9% in the second quarter. Quinn Opportunity Partners LLC now owns 42,000 shares of the company’s stock valued at $871,000 after buying an additional 20,000 shares during the period. Finally, PNC Financial Services Group Inc. increased its position in shares of Structure Therapeutics by 29.1% during the second quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock worth $92,000 after acquiring an additional 994 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.